New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion ...
LYON, France, March 21, 2023 -- EDAP TMS SA (EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced a recent presentation of positive results from a large, ...
GENEVA, April 16, 2025 /PRNewswire/ -- Spineart, a fast-growing company in spine surgery innovation, today announces that it has completed a planned interim analysis for its 2-level BAGUERA® C IDE ...
A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers ...
AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain -In this open-label study, the Sufentanil ...
Novartis NVS reported positive top-line data from a late-stage study of its investigational new malaria treatment candidate, KLU156 (ganaplacide/lumefantrine, or ...
(RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) announced topline results from a Phase 3 study of weekly self-administered subcutaneous ULTOMIRIS in adults with paroxysmal nocturnal hemoglobinuria.
TOKYO, June 8, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from the Phase 3 DOLOMITES study, evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback